First Tracks Biotherapeutics has entered into a securities purchase agreement with several third-party investors for a private placement expected to generate approximately $200 million in gross proceeds. Under the agreement, the company will issue and sell over 6.1 million unregistered shares of its common stock.
Key Details
- Transaction: Sale of 6,106,870 shares of common stock in a private placement at a purchase price of $32.75 per share.
- Proceeds: The company expects to receive aggregate gross proceeds of approximately $200 million, before deducting placement agent fees and other expenses.
- Timeline: The private placement was announced on October 15, 2026, and is expected to close on or about October 19, 2026, subject to customary closing conditions.
- Registration Rights: In connection with the placement, First Tracks will file a registration statement with the SEC within 30 days of closing to cover the resale of the shares sold to the investors.